New hope: immune drug before surgery for tough colorectal cancer
NCT ID NCT07352280
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving the drug tislelizumab before surgery can help people with a certain type of colorectal cancer (dMMR/MSI-H). About 30 adults with stage II or III cancer will get three doses of the drug, then have surgery. Researchers will check if the cancer disappears and watch for side effects over 5 years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLO-RECTAL CANCER (DMMR/MSI-H CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Undefined, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.